NOT FOR DISTRIBUTION
Header cover image

Global Cord Blood

Market Cap

€485.3m

Last Updated

2021/04/14 18:57 UTC

Data Sources

Company Financials

Executive Summary

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. More Details


Snowflake Analysis

Flawless balance sheet and undervalued.


Similar Companies

Share Price & News

How has Global Cord Blood's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6CB is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 6CB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.


Market Performance


7 Day Return

4.9%

6CB

0.9%

DE Healthcare

0.2%

DE Market


1 Year Return

45.5%

6CB

0.6%

DE Healthcare

42.4%

DE Market

Return vs Industry: 6CB exceeded the German Healthcare industry which returned 0.6% over the past year.

Return vs Market: 6CB matched the German Market which returned 42.4% over the past year.


Shareholder returns

6CBIndustryMarket
7 Day4.9%0.9%0.2%
30 Day4.3%5.2%5.1%
90 Day20.8%-2.9%9.6%
1 Year45.5%45.5%2.6%0.6%47.0%42.4%
3 Year-48.7%-49.2%-27.9%-31.4%23.5%12.8%
5 Year-29.7%-30.4%-28.5%-33.1%51.0%29.5%

Long-Term Price Volatility Vs. Market

How volatile is Global Cord Blood's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Global Cord Blood undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 6CB (€3.84) is trading below our estimate of fair value (€10.91)

Significantly Below Fair Value: 6CB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 6CB is good value based on its PE Ratio (7.9x) compared to the DE Healthcare industry average (32.5x).

PE vs Market: 6CB is good value based on its PE Ratio (7.9x) compared to the German market (28.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6CB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6CB is good value based on its PB Ratio (0.9x) compared to the DE Healthcare industry average (1.7x).


Future Growth

How is Global Cord Blood forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Global Cord Blood has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Global Cord Blood performed over the past 5 years?

35.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6CB has high quality earnings.

Growing Profit Margin: 6CB's current net profit margins (41.3%) are higher than last year (39.6%).


Past Earnings Growth Analysis

Earnings Trend: 6CB's earnings have grown significantly by 35.1% per year over the past 5 years.

Accelerating Growth: 6CB's earnings growth over the past year (2.7%) is below its 5-year average (35.1% per year).

Earnings vs Industry: 6CB earnings growth over the past year (2.7%) exceeded the Healthcare industry 2%.


Return on Equity

High ROE: 6CB's Return on Equity (11.4%) is considered low.


Financial Health

How is Global Cord Blood's financial position?


Financial Position Analysis

Short Term Liabilities: 6CB's short term assets (CN¥6.1B) exceed its short term liabilities (CN¥591.5M).

Long Term Liabilities: 6CB's short term assets (CN¥6.1B) exceed its long term liabilities (CN¥2.9B).


Debt to Equity History and Analysis

Debt Level: 6CB is debt free.

Reducing Debt: 6CB has no debt compared to 5 years ago when its debt to equity ratio was 56.8%.

Debt Coverage: 6CB has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 6CB has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Global Cord Blood current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6CB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6CB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6CB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6CB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 6CB is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6CB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average board tenure


CEO

Tina Zheng (48 yo)

no data

Tenure

CN¥7,324,757

Compensation

Ms. Ting Zheng, also known as Tina, serves as the Chief Executive Officer and Chief Executive Officer of Beijing Division of Global Cord Blood Corporation (formerly known as China Cord Blood Corporation) a...


CEO Compensation Analysis

Compensation vs Market: Tina's total compensation ($USD1.12M) is about average for companies of similar size in the German market ($USD922.49K).

Compensation vs Earnings: Tina's compensation has increased by more than 20% in the past year.


Board Members

Experienced Board: 6CB's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Global Cord Blood Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Global Cord Blood Corporation
  • Ticker: 6CB
  • Exchange: DB
  • Founded: NaN
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$581.014m
  • Listing Market Cap: US$485.263m
  • Shares outstanding: 121.55m
  • Website: https://www.globalcordbloodcorp.com

Number of Employees


Location

  • Global Cord Blood Corporation
  • Bank of China Tower
  • 48th Floor
  • Central
  • Hong Kong

Listings


Biography

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, process...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/14 18:57
End of Day Share Price2021/04/14 00:00
Earnings2020/12/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.